UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 570

Sortiert nach

The incidence and magnitude of fibrinolytic activation in trauma patients

Journal of thrombosis and haemostasis, 2013-02, Vol.11 (2), p.307-314

2013

Volltextzugriff (PDF)

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.487-498

2016

Volltextzugriff (PDF)

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.697-704

2017

Volltextzugriff (PDF)

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

Journal of thrombosis and haemostasis, 2014-11, Vol.12 (11), p.1788-1800

2014

Volltextzugriff (PDF)

Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis

Journal of thrombosis and haemostasis, 2016-11, Vol.14 (11), p.2141-2147

2016

Volltextzugriff (PDF)

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.72-80

2016

Volltextzugriff (PDF)

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-05, Vol.10 (3), p.218-231

2004

Volltextzugriff (PDF)

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-05, Vol.10 (3), p.199-217

2004

Volltextzugriff (PDF)

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-07, Vol.21 (4), p.490-495

2015

Volltextzugriff (PDF)

Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-11, Vol.20 (6), p.846-853

2014

Volltextzugriff (PDF)

Access to primary dental care for patients with inherited bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (4), p.510-515

2012

Volltextzugriff (PDF)

Fatal postoperative pulmonary embolism in mild haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2006-03, Vol.12 (2), p.179-182

2006

Volltextzugriff (PDF)

Thrombotic risk factors associated with transurethral prostatectomy

BJU international, 1999-06, Vol.83 (9), p.984-989

1999

Volltextzugriff (PDF)

Type 1 von Willebrand disease — a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history

British journal of haematology, 2000-02, Vol.108 (2), p.259-264

2000

Volltextzugriff (PDF)

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

The New England journal of medicine, 2022-03, Vol.386 (11), p.1013-1025

2022

Volltextzugriff (PDF)

von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use

Thrombosis and haemostasis, 1997-10, Vol.78 (4), p.1272

1997

Volltextzugriff (PDF)

Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling

Thrombosis and haemostasis, 2000-12, Vol.84 (6), p.998

2000

Volltextzugriff (PDF)

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

British journal of haematology, 1996-05, Vol.93 (2), p.457-459

1996

Volltextzugriff (PDF)

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

The New England journal of medicine, 2017-08, Vol.377 (9), p.819-828

2017

Volltextzugriff (PDF)

Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor

Thrombosis and haemostasis, 2000-08, Vol.84 (2), p.188

2000

Volltextzugriff (PDF)

A framework for genetic service provision for haemophilia and other inherited bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2005-03, Vol.11 (2), p.145-163

2005

Volltextzugriff (PDF)

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period

Clinical and laboratory haematology, 2000-10, Vol.22 (5), p.275-278

2000

Volltextzugriff (PDF)

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

Haemophilia : the official journal of the World Federation of Hemophilia, 2002-03, Vol.8 (2), p.91-97

2002

Volltextzugriff (PDF)

Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product

Thrombosis and haemostasis, 1997-09, Vol.78 (3), p.1027

1997

Volltextzugriff (PDF)

Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97

British journal of haematology, 1999-03, Vol.104 (4), p.909-914

1999

Volltextzugriff (PDF)

1 – 25 von 570

Suche als RSS-Feed

Aktive Filter

KollektionIEEE Xplore

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(544)
Mit Volltextzugriff
(511)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The incidence and magnitude of fibrinolytic activation in trauma patients

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres

Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience

Access to primary dental care for patients with inherited bleeding disorders

Fatal postoperative pulmonary embolism in mild haemophilia

Thrombotic risk factors associated with transurethral prostatectomy

Type 1 von Willebrand disease — a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use

Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor

A framework for genetic service provision for haemophilia and other inherited bleeding disorders

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product

Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97

Aktive Filter

Suchergebnisse filtern